BR112023002089A2 - Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 - Google Patents
Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4Info
- Publication number
- BR112023002089A2 BR112023002089A2 BR112023002089A BR112023002089A BR112023002089A2 BR 112023002089 A2 BR112023002089 A2 BR 112023002089A2 BR 112023002089 A BR112023002089 A BR 112023002089A BR 112023002089 A BR112023002089 A BR 112023002089A BR 112023002089 A2 BR112023002089 A2 BR 112023002089A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- smarca2
- smarca4
- degradators
- pyridazine compounds
- Prior art date
Links
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 title abstract 3
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 title abstract 3
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 title abstract 3
- 102100031027 Transcription activator BRG1 Human genes 0.000 title abstract 3
- -1 6- SUBSTITUTED PYRIDAZINE COMPOUNDS Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000001064 degrader Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical class C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSTOS DE PIRIDAZINA 6-SUBSTITUÍDOS COMO DEGRADADORES DE SMARCA2 E/OU SMARCA4. A presente invenção fornece compostos de piridazina 6-substituídos da fórmula (I), que são terapeuticamente úteis como degradadores de SMARCA2 e/ou SMARCA4. Esses compostos são úteis no tratamento e/ou no retardo da progressão de doenças ou distúrbios dependentes de SMARCA2 e/ou SMARCA4 em um indivíduo. A presente invenção também fornece a preparação dos compostos e das composições farmacêuticas que compreendem pelo menos um dos compostos da fórmula (I), ou um sal farmaceuticamente aceitável, ou um estereoisômero, ou um tautômero, ou um pró-fármaco dos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041033326 | 2020-08-04 | ||
| PCT/IB2021/057089 WO2022029617A1 (en) | 2020-08-04 | 2021-08-03 | 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002089A2 true BR112023002089A2 (pt) | 2023-02-28 |
Family
ID=80117730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002089A BR112023002089A2 (pt) | 2020-08-04 | 2021-08-03 | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240018134A1 (pt) |
| EP (1) | EP4192835A1 (pt) |
| JP (1) | JP2023536504A (pt) |
| KR (1) | KR20230061349A (pt) |
| CN (1) | CN116529250A (pt) |
| AU (1) | AU2021320052A1 (pt) |
| BR (1) | BR112023002089A2 (pt) |
| CA (1) | CA3188024A1 (pt) |
| IL (1) | IL300387A (pt) |
| MX (1) | MX2023001445A (pt) |
| WO (1) | WO2022029617A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics Inc | SMARCA DEGRADERS AND USES THEREOF |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN |
| CN112771038A (zh) * | 2018-04-26 | 2021-05-07 | 奥里吉恩发现科技有限公司 | 作为smarca2/4降解剂的哒嗪衍生物 |
-
2021
- 2021-08-03 KR KR1020237005345A patent/KR20230061349A/ko unknown
- 2021-08-03 CA CA3188024A patent/CA3188024A1/en active Pending
- 2021-08-03 MX MX2023001445A patent/MX2023001445A/es unknown
- 2021-08-03 CN CN202180068383.4A patent/CN116529250A/zh active Pending
- 2021-08-03 US US18/019,721 patent/US20240018134A1/en active Pending
- 2021-08-03 BR BR112023002089A patent/BR112023002089A2/pt unknown
- 2021-08-03 EP EP21852975.8A patent/EP4192835A1/en active Pending
- 2021-08-03 WO PCT/IB2021/057089 patent/WO2022029617A1/en active Application Filing
- 2021-08-03 IL IL300387A patent/IL300387A/en unknown
- 2021-08-03 AU AU2021320052A patent/AU2021320052A1/en active Pending
- 2021-08-03 JP JP2023507923A patent/JP2023536504A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192835A1 (en) | 2023-06-14 |
| CN116529250A (zh) | 2023-08-01 |
| MX2023001445A (es) | 2023-05-08 |
| US20240018134A1 (en) | 2024-01-18 |
| CA3188024A1 (en) | 2022-02-10 |
| JP2023536504A (ja) | 2023-08-25 |
| AU2021320052A1 (en) | 2023-03-23 |
| WO2022029617A1 (en) | 2022-02-10 |
| IL300387A (en) | 2023-04-01 |
| KR20230061349A (ko) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| PH12020551927A1 (en) | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| PH12021551274A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
| EP4356973A3 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
| CR20220675A (es) | Análogos de nucleósido de 1´- ciano y usos de los mismos | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| BR112017024933A2 (pt) | alvocidib produce com a bioavailabilidade aumentada | |
| DK1427708T3 (da) | Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| EA202191801A1 (ru) | Гетероциклические ингибиторы mat2a и способы применения для лечения рака | |
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| BR112018007128A2 (pt) | compostos para a inibição de câncer e epigênese | |
| CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112023002089A2 (pt) | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 |